Bioservo Technologies (BIOS.ST) Stock Analysis & AI Equity Report
Bioservo Technologies (BIOS.ST) overview
Bioservo Technologies (BIOS.ST) stock analysis and AI equity research. For the latest completed financial year, 2022, Bioservo Technologies reported revenue of SEK 9.6m and operating profit of SEK -50.6m; the year-end share price was 1.92 SEK and market capitalisation was SEK 37.8m. Bioservo Technologies is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Bioservo Technologies's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Bioservo Technologies
Bioservo Technologies develops and sells wearable muscle-strengthening systems, with a focus on soft exoskeleton technology for the hand. Its main product, Carbonhand, is designed to support people with impaired hand function in daily activities and clinical use. In 2024, the company said it would focus on the life science market after transferring Ironhand rights to Skelex.
Generate the Bioservo Technologies report
Bioservo Technologies is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Bioservo Technologies and represent the latest completed financial year (2022). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.